Phreesia, Inc. (NYSE:PHR) Director Sells $514,947.60 in Stock

Phreesia, Inc. (NYSE:PHR) Director Michael Weintraub sold 20,565 shares of the company’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $25.04, for a total value of $514,947.60. Following the completion of the transaction, the director now directly owns 242,827 shares in the company, valued at approximately $6,080,388.08. The trade was a 7.81 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael Weintraub also recently made the following trade(s):

• On Monday, December 16th, Michael Weintraub sold 861 shares of Phreesia stock. The shares were sold at an average price of $25.26, for a total transaction of $21,748.86.
• On Monday, December 2nd, Michael Weintraub sold 15,152 shares of Phreesia stock. The shares were sold at an average price of $21.01, for a total value of $318,343.52.

Phreesia Stock Down 3.0 %

Shares of NYSE:PHR opened at $24.87 on Wednesday. Phreesia, Inc. has a 52-week low of $17.07 and a 52-week high of $29.16. The company has a quick ratio of 1.77, a current ratio of 1.74 and a debt-to-equity ratio of 0.04. The business has a fifty day moving average of $20.60 and a two-hundred day moving average of $21.88. The stock has a market cap of $1.45 billion, a P/E ratio of -16.92 and a beta of 0.98.

Phreesia (NYSE:PHR) last released its quarterly earnings data on Monday, December 9th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.04. The firm had revenue of $106.80 million during the quarter, compared to analysts’ expectations of $106.33 million. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. Phreesia’s revenue was up 16.6% compared to the same quarter last year. During the same period last year, the business earned ($0.58) earnings per share. On average, research analysts expect that Phreesia, Inc. will post -1.16 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp raised its position in Phreesia by 8.4% in the second quarter. Bank of New York Mellon Corp now owns 214,430 shares of the company’s stock valued at $4,546,000 after purchasing an additional 16,614 shares during the period. Peregrine Capital Management LLC raised its holdings in Phreesia by 11.3% in the 2nd quarter. Peregrine Capital Management LLC now owns 354,607 shares of the company’s stock valued at $7,518,000 after buying an additional 36,047 shares during the period. nVerses Capital LLC lifted its position in Phreesia by 76.5% in the second quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock valued at $64,000 after buying an additional 1,300 shares during the last quarter. Rhumbline Advisers boosted its stake in Phreesia by 1.0% during the second quarter. Rhumbline Advisers now owns 82,136 shares of the company’s stock worth $1,741,000 after buying an additional 853 shares during the period. Finally, Arcadia Investment Management Corp MI raised its stake in shares of Phreesia by 13.9% in the 2nd quarter. Arcadia Investment Management Corp MI now owns 88,625 shares of the company’s stock valued at $1,879,000 after acquiring an additional 10,800 shares during the period. 92.10% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Truist Financial lifted their price target on Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. JPMorgan Chase & Co. increased their price target on shares of Phreesia from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Monday, September 9th. Needham & Company LLC reiterated a “buy” rating and issued a $29.00 price objective on shares of Phreesia in a research report on Tuesday, December 10th. Robert W. Baird dropped their target price on Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $34.00 price target on shares of Phreesia in a report on Thursday, September 5th. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $29.33.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.